Novel Gd Nanoparticles Enhance Vascular Contrast for High-Resolution Magnetic Resonance Imaging
Open Access
- 30 September 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 5 (9), e13082
- https://doi.org/10.1371/journal.pone.0013082
Abstract
Gadolinium (Gd), with its 7 unpaired electrons in 4f orbitals that provide a very large magnetic moment, is proven to be among the best agents for contrast enhanced MRI. Unfortunately, the most potent MR contrast agent based on Gd requires relatively high doses of Gd. The Gd-chelated to diethylene-triamine-penta-acetic acid (DTPA), or other derivatives (at 0.1 mmole/kg recommended dose), distribute broadly into tissues and clear through the kidney. These contrast agents carry the risk of Nephrogenic Systemic Fibrosis (NSF), particularly in kidney impaired subjects. Thus, Gd contrast agents that produce higher resolution images using a much lower Gd dose could address both imaging sensitivity and Gd safety. To determine whether a biocompatible lipid nanoparticle with surface bound Gd can improve MRI contrast sensitivity, we constructed Gd-lipid nanoparticles (Gd-LNP) containing lipid bound DTPA and Gd. The Gd-LNP were intravenously administered to rats and MR images collected. We found that Gd in Gd-LNP produced a greater than 33-fold higher longitudinal (T1) relaxivity, r1, constant than the current FDA approved Gd-chelated contrast agents. Intravenous administration of these Gd-LNP at only 3% of the recommended clinical Gd dose produced MRI signal-to-noise ratios of greater than 300 in all vasculatures. Unlike current Gd contrast agents, these Gd-LNP stably retained Gd in normal vasculature, and are eliminated predominately through the biliary, instead of the renal system. Gd-LNP did not appear to accumulate in the liver or kidney, and was eliminated completely within 24 hrs. The novel Gd-nanoparticles provide high quality contrast enhanced vascular MRI at 97% reduced dose of Gd and do not rely on renal clearance. This new agent is likely to be suitable for patients exhibiting varying degrees of renal impairment. The simple and adaptive nanoparticle design could accommodate ligand or receptor coating for drug delivery optimization and in vivo drug-target definition in system biology profiling, increasing the margin of safety in treatment of cancers and other diseases.Keywords
This publication has 11 references indexed in Scilit:
- A high relaxivity Gd(III)DOTA-DSPE-based liposomal contrast agent for magnetic resonance imagingEuropean Journal of Pharmaceutics and Biopharmaceutics, 2009
- Nanoparticle pharmacokinetic profiling in vivo using magnetic resonance imagingMagnetic Resonance in Medicine, 2008
- Nephrogenic Systemic Fibrosis: A Chemical PerspectiveRadiology, 2008
- Recent advances in contrast-enhanced magnetic resonance angiography.2007
- Superparamagnetic gadonanotubes are high-performance MRI contrast agentsChemical Communications, 2005
- Causes and mechanisms of hypoalbuminaemiaClinical Nutrition, 2001
- MS-325: albumin-targeted contrast agent for MR angiography.Radiology, 1998
- Controlled delivery of Gd-containing liposomes to lymph nodes: surface modification may enhance MRI contrast propertiesMagnetic Resonance Imaging, 1995
- Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice.1992
- Nuclear Magnetic Interactions in the HF MoleculeThe Journal of Chemical Physics, 1956